Sep 05, 2024 8:22 am EDT OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference
Aug 29, 2024 7:53 am EDT OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose
Jul 31, 2024 6:21 pm EDT OS Therapies Announces Pricing of its Initial Public Offering on NYSE American - Company to Trade under Symbol “OSTX”
Jul 24, 2024 10:48 am EDT OS Therapies Announces Positive Safety Data from Phase 1 Clinical Trial of OST-HER2 in HER2-Expressing Breast Cancer and in Preclinical Efficacy in Models of Breast Cancer